PMID- 38130769
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240210
IS  - 2473-4039 (Electronic)
IS  - 2473-4039 (Linking)
VI  - 7
IP  - 12
DP  - 2023 Dec
TI  - New Human Leukocyte Antigen (HLA) Antibody Formation and Creatinine Elevation 
      With Abaloparatide in Kidney Transplant Recipient.
PG  - e10814
LID - 10.1002/jbm4.10814 [doi]
LID - e10814
AB  - A 39-year-old female with a history of kidney transplant presented to the 
      endocrinology clinic for osteoporosis evaluation after sustaining an ankle 
      fracture from a fall. Her kidney transplant regimen (mycophenolate mofetil 360 mg 
      twice a day, tacrolimus 0.5 mg every morning and 0.5-1 mg every evening, 
      prednisone 5 mg/day) and baseline creatinine (1.0-1.2 mg/dL) had been stable for 
      several years. After an appropriate secondary workup, she was started on 
      abaloparatide 80 mug subcutaneous daily injections for osteoporosis. She had a 
      good initial biochemical response to therapy. However, 5 months after 
      abaloparatide initiation she was found to have a new elevation in serum 
      creatinine (1.17 to 1.69 mg/dL) despite stable serum tacrolimus trough levels, 
      and two new human leukocyte antigen (HLA) antibodies (anti-HLA antibodies 
      detected to Cw7 and DP28). Abaloparatide was stopped due to concern for 
      immunogenicity. There was no evidence of rejection on kidney biopsy and she was 
      restabilized on her transplant regimen with a new baseline creatinine of 
      1.3-1.6 mg/dL. The patient was subsequently started on teriparatide 20 mug daily 
      subcutaneous injections for 2 years with good biochemical response, significant 
      improvement in bone mineral density, and stable transplant regimen without 
      additional signs of immunogenicity or rejection. This is the first case report to 
      raise concern about immunogenicity with abaloparatide in solid organ transplant 
      recipients. (c) 2023 The Authors. JBMR Plus published by Wiley Periodicals LLC on 
      behalf of American Society for Bone and Mineral Research.
CI  - (c) 2023 The Authors. JBMR Plus published by Wiley Periodicals LLC on behalf of 
      American Society for Bone and Mineral Research.
FAU - Swanson, Christine M
AU  - Swanson CM
AUID- ORCID: 0000-0003-1554-0862
AD  - Division of Endocrinology, Metabolism and Diabetes University of Colorado 
      Anschutz Medical Campus Aurora CO USA.
AD  - Eastern Colorado VA Geriatric, Research, Education, and Clinical Center (GRECC) 
      Aurora CO USA.
FAU - Krohn, Kelly
AU  - Krohn K
AD  - The Core Institute Phoenix AZ USA.
FAU - Wiseman, Alexander
AU  - Wiseman A
AD  - Division of Nephrology Centura Transplant Denver CO USA.
FAU - Rothman, Micol S
AU  - Rothman MS
AD  - Division of Endocrinology, Metabolism and Diabetes University of Colorado 
      Anschutz Medical Campus Aurora CO USA.
LA  - eng
GR  - R01 HL151332/HL/NHLBI NIH HHS/United States
PT  - Case Reports
DEP - 20230921
PL  - England
TA  - JBMR Plus
JT  - JBMR plus
JID - 101707013
PMC - PMC10731105
OTO - NOTNLM
OT  - ABALOPARATIDE
OT  - IMMUNOGENICITY
OT  - KIDNEY TRANSPLANT
OT  - OSTEOPOROSIS
OT  - TERIPARATIDE
EDAT- 2023/12/22 06:42
MHDA- 2023/12/22 06:43
PMCR- 2023/09/21
CRDT- 2023/12/22 04:00
PHST- 2023/05/16 00:00 [received]
PHST- 2023/07/27 00:00 [revised]
PHST- 2023/08/18 00:00 [accepted]
PHST- 2023/12/22 06:43 [medline]
PHST- 2023/12/22 06:42 [pubmed]
PHST- 2023/12/22 04:00 [entrez]
PHST- 2023/09/21 00:00 [pmc-release]
AID - JBM410814 [pii]
AID - 10.1002/jbm4.10814 [doi]
PST - epublish
SO  - JBMR Plus. 2023 Sep 21;7(12):e10814. doi: 10.1002/jbm4.10814. eCollection 2023 
      Dec.